John C. Wang, MD
John Wang, MD, is a strong believer in the potential benefits to patients of participating in clinical trials. As chief of the Cardiac Catheterization Laboratory at MedStar Union Memorial Hospital and scientific director for Baltimore Cardiovascular Research, he has seen first-hand how end-stage heart disease patients were given a new lease on life from therapies offered in clinical trials at MedStar Health.
Under Dr. Wang’s leadership, the interventional cardiology service at MedStar is a leader in enrolling patients in clinical trials testing therapies ranging from TAVR to new kinds of stents, which are used to prop open blocked blood vessels.
Dr. Wang is board certified in Interventional Cardiology, Cardiovascular Disease and Internal Medicine. He specializes in minimally invasive procedures that increase blood flow to the heart, diminish chest pain, and decrease the risk of heart attack.
Dr. Wang and his team perform more than 5,000 procedures a year. He finds great satisfaction in how quickly a patient's quality of life improves with the latest techniques in angioplasty, stenting and catheterization. Using an advanced procedure known as trans-radial cardiac catheterization, performed through the patient's wrist, Dr. Wang offers patients a less-invasive, safer option than traditional catheterization, as well as a quicker recovery time and shorter hospital stay.
Dr. Wang also performs transcatheter aortic valve replacements (also known as TAVR). He replaces a patient's aortic valve via a small catheter placed through the femoral artery without traditional open-heart surgery. MedStar Union Memorial Hospital is one of the few hospitals in the region to offer these procedures.
Widely published, Dr. Wang has been the principal investigator or sub-investigator on more than 40 studies relating to the safety and efficacy of new devices and technology in interventional cardiology. Currently, he is the national principal investigator of the OMEGA trial studying the latest generation of bare metal stents.
Dr. Wang’s undergraduate and medical degrees are from the University of Chicago. He also earned a Master of Science in Epidemiology from the Harvard School of Public Health. In 2017, he was named a “Top Doc” by Baltimore Magazine for interventional cardiology.
Research Study in Focus: Discovering New Technologies to Treat Heart Disease
MedStar Cardiovascular Research Network, the research division of the MedStar Heart & Vascular Institute, integrates research with clinical care at every level. Originating at MedStar Washington Hospital Center, this culture creates an environment that fosters an accelerated pace of discovery and the delivery of safer, more effective treatment. For this reason, MedStar Heart & Vascular Institute is considered a pioneer for advanced therapies. Read more...
Transcatheter aortic valve replacement (TAVR) is a recent example of nationally leading cardiology research conducted by MedStar. TAVR was developed to reduce advanced aortic valve disease for patients who are considered to have at least an intermediate risk for open heart valve replacement.For patients who are too ill to undergo open heart valve replacement, TAVR is a much safer option with a significantly shorter recovery period. MedStar Heart & Vascular Institute was the fourth cardiac center in the country to perform clinical trials on the TAVR procedure and one of the top five cardiac centers in the nation for this procedure. MedStar Union Memorial Hospital is also the first and only location in Maryland to offer to our communities the fully dissolvable cardiac stent for patients fighting coronary artery disease.